These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 31413541)
1. Clinical utility of ramucirumab in non-small-cell lung cancer. Uprety D Biologics; 2019; 13():133-137. PubMed ID: 31413541 [TBL] [Abstract][Full Text] [Related]
2. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Nakagawa K; Garon EB; Seto T; Nishio M; Ponce Aix S; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Imamura F; Yoh K; Shih JY; Au KH; Moro-Sibilot D; Enatsu S; Zimmermann A; Frimodt-Moller B; Visseren-Grul C; Reck M; Lancet Oncol; 2019 Dec; 20(12):1655-1669. PubMed ID: 31591063 [TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Yoh K; Hosomi Y; Kasahara K; Yamada K; Takahashi T; Yamamoto N; Nishio M; Ohe Y; Koue T; Nakamura T; Enatsu S; Lee P; Ferry D; Tamura T; Nakagawa K Lung Cancer; 2016 Sep; 99():186-93. PubMed ID: 27565938 [TBL] [Abstract][Full Text] [Related]
4. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Garon EB; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Gorbunova V; Kowalyszyn RD; Pikiel J; Czyzewicz G; Orlov SV; Lewanski CR; Thomas M; Bidoli P; Dakhil S; Gans S; Kim JH; Grigorescu A; Karaseva N; Reck M; Cappuzzo F; Alexandris E; Sashegyi A; Yurasov S; Pérol M Lancet; 2014 Aug; 384(9944):665-73. PubMed ID: 24933332 [TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, phase III study of Docetaxel and Ramucirumab versus Docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study design. Garon EB; Cao D; Alexandris E; John WJ; Yurasov S; Perol M Clin Lung Cancer; 2012 Nov; 13(6):505-9. PubMed ID: 22853980 [TBL] [Abstract][Full Text] [Related]
6. Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. Reck M; Paz-Ares L; Bidoli P; Cappuzzo F; Dakhil S; Moro-Sibilot D; Borghaei H; Johnson M; Jotte R; Pennell NA; Shepherd FA; Tsao A; Thomas M; Carter GC; Chan-Diehl F; Alexandris E; Lee P; Zimmermann A; Sashegyi A; Pérol M Lung Cancer; 2017 Oct; 112():181-187. PubMed ID: 29191593 [TBL] [Abstract][Full Text] [Related]
7. Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results. Reck M; Garon EB; Paz-Ares L; Ponce S; Jaime JC; Juan O; Nadal E; Kiura K; Widau RC; He S; Dalal R; Lee P; Nakagawa K Clin Lung Cancer; 2018 May; 19(3):213-220.e4. PubMed ID: 29317191 [TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated Yoh K; Atagi S; Reck M; Garon EB; Ponce Aix S; Moro-Sibilot D; Winfree KB; Frimodt-Moller B; Zimmermann A; Visseren-Grul C; Nakagawa K; Curr Med Res Opin; 2020 Oct; 36(10):1667-1675. PubMed ID: 32780643 [TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review. Garon EB; Visseren-Grul C; Rizzo MT; Puri T; Chenji S; Reck M Front Oncol; 2023; 13():1247879. PubMed ID: 37731641 [TBL] [Abstract][Full Text] [Related]
10. U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy. Larkins E; Scepura B; Blumenthal GM; Bloomquist E; Tang S; Biable M; Kluetz P; Keegan P; Pazdur R Oncologist; 2015 Nov; 20(11):1320-5. PubMed ID: 26446239 [TBL] [Abstract][Full Text] [Related]
11. Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer. Paz-Ares LG; Pérol M; Ciuleanu TE; Kowalyszyn RD; Reck M; Lewanski CR; Syrigos K; Arrieta O; Prabhash K; Park K; Pikiel J; Göksel T; Lee P; Zimmermann A; Carter GC; Alexandris E; Garon EB Lung Cancer; 2017 Oct; 112():126-133. PubMed ID: 29191585 [TBL] [Abstract][Full Text] [Related]
12. Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancer. Pérol M; Winfree KB; Cuyun Carter G; Lin Cui Z; Bowman L; Garon EB Lung Cancer; 2019 May; 131():6-13. PubMed ID: 31027699 [TBL] [Abstract][Full Text] [Related]
13. Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy. Garon EB; Scagliotti GV; Gautschi O; Reck M; Thomas M; Iglesias Docampo L; Kalofonos H; Kim JH; Gans S; Brustugun OT; Orlov SV; Cuyun Carter G; Zimmermann AH; Oton AB; Alexandris E; Lee P; Wolff K; Stefaniak VJ; Socinski MA; Pérol M ESMO Open; 2020 Jan; 5(1):. PubMed ID: 31958290 [TBL] [Abstract][Full Text] [Related]
14. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Doebele RC; Spigel D; Tehfe M; Thomas S; Reck M; Verma S; Eakle J; Bustin F; Goldschmidt J; Cao D; Alexandris E; Yurasov S; Camidge DR; Bonomi P Cancer; 2015 Mar; 121(6):883-92. PubMed ID: 25377507 [TBL] [Abstract][Full Text] [Related]
15. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis. Ponce Aix S; Novello S; Garon EB; Nakagawa K; Nadal E; Moro-Sibilot D; Alonso Garcia M; Fabre E; Frimodt-Moller B; Zimmermann AH; Visseren-Grul CM; Reck M; Cancer Treat Res Commun; 2021; 27():100378. PubMed ID: 33905962 [TBL] [Abstract][Full Text] [Related]
16. RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability. Nadal E; Horinouchi H; Shih JY; Nakagawa K; Reck M; Garon EB; Wei YF; Kollmeier J; Frimodt-Moller B; Barrett E; Lipkovich O; Visseren-Grul C; Novello S Drug Saf; 2022 Jan; 45(1):45-64. PubMed ID: 34928484 [TBL] [Abstract][Full Text] [Related]
17. The Role of the Antiangiogenetic Ramucirumab in the Treatment of Advanced Non Small Cell Lung Cancer. Maione P; Sgambato A; Casaluce F; Sacco PC; Santabarbara G; Rossi A; Gridelli C Curr Med Chem; 2017; 24(1):3-13. PubMed ID: 27855622 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial. Ramalingam SS; Pérol M; Reck M; Kowalyszyn RD; Gautschi O; Kimmich M; Cho EK; Czyzewicz G; Grigorescu A; Karaseva N; Dakhil S; Lee P; Zimmerman A; Sashegyi A; Alexandris E; Carter GC; Winfree KB; Garon EB Clin Lung Cancer; 2018 May; 19(3):270-279.e3. PubMed ID: 29373274 [TBL] [Abstract][Full Text] [Related]
19. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain S; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Hegemann M; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Del Muro XG; Rodriguez-Vida A; Cicin I; Harputluoglu H; Widau RC; Liepa AM; Walgren RA; Hamid O; Zimmermann AH; Bell-McGuinn KM; Powles T; Lancet; 2017 Nov; 390(10109):2266-2277. PubMed ID: 28916371 [TBL] [Abstract][Full Text] [Related]